Cooney Charles Leland reduced his holdings in INNOVENT BIO (01801) by approximately 38,600 shares at a price of about HKD 107.99 per share.
The latest number of shares held after the reduction is approximately 151,800 shares, with the latest holding ratio at 0.01%.
According to the latest data from the Hong Kong Stock Exchange, on August 27, Cooney Charles Leland reduced his holdings in INNOVENT BIO (01801) by 38,628 shares, at a price of HKD 107.9934 per share, for a total amount of approximately HKD 4.1716 million. After the reduction, the latest number of shares held is approximately 151,800, with a new holding percentage of 0.01%.
Related Articles
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.
Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.
Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.
Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.
Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
RECOMMEND
